F. Kourgia, M. Vini, E. Zervou

Slides:

Advertisements

Similar presentations

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.

Advertisements

HCV Assays: Impact on HCV Studies & Update on HCV blood bank protocol.

A PROSPECTIVE STUDY OF POLYMERASE CHAIN REACTION TESTING ON POOLED PLASMA VS. INDIVIDUAL DONATION HIV P24 TESTING.

6/03/031 Hepatitis C –Update Laboratory Issues Hema Kapoor MD. SM Virology Section Manager Bureau of Laboratories Michigan Department of Community Health.

Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013.

Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:

Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA

Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:

The Safety of the Blood Supply

Hepatitis C Best Practice Guidelines Susan Thompson, RN, MPH September 2009.

Ad Hoc Disease Transmission Advisory Committee Spring 2015.

Acute Viral Hepatitis. Viral Hepatitis Infectious: Hepatitis A Infectious: Hepatitis A Serum : Hepatitis B, D Serum : Hepatitis B, D NANB : Hepatitis.

Molecular Diagnosis of Infectious Diseases. Why use a molecular test to diagnose an infectious disease? Need an accurate and timely diagnosis Important.

Epidemiology and Prevention of Viral Hepatitis A to E: Hepatitis Branch Centers for Disease Control and Prevention An Overview.

Treviso, 21 October Karin Magnussen. Donors outside the Blood Bank /Centre Donors in the Blood Bank /Centre Blood products Blood Group serology The Patients.

Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.

HIV Testing CDC power point edited by M. Myers

Management of Risk and Blood Availability in Donor Populations with High Prevalence of Blood Borne Pathogens Ravi Reddy IBSF Meeting 20 March 2015.

Testing Source Plasma for Hepatitis B Virus by Nucleic Acid Testing Blood Products Advisory Committee Meeting Blood Products Advisory Committee Meeting.

Guidelines for Laboratory Testing and Result Reporting for Antibody to Hepatitis C Virus Miriam J. Alter, Ph.D. Division of Viral Hepatitis Centers for.

Terry Kotrla, MS, MT(ASCP)BB MLAB 2431 Immunohematology Unit 1 Part 2 Blood Collection.

Transfusion of Blood Product History: 1920:Sodium citrate anticoagulant(10 days storage) 1958: Plastic bag of transfusion 1656: Initial theory and.

Immunohematology (Blood Bank) CLS 245. What is Immunohematology? It is the study of Antigen-Antibody reaction as they relate to blood disorder.

PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.

E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.

Limitations of HBsAg testing in the screening of blood donors Wolfram H. Gerlich Institute of Medical Virology University Giessen, Germany SoGAT XVI Langen.

Lookback study for transfusion- related HBV infection in Japan Tokyo Metropolitan Red Cross Blood Center Masahiro Satake.

Pooled Source Plasma NAT for HIV-1 An Update from the Bayer HIV-1 IND Study Barbara Masecar Bayer Corporation Raleigh, NC Blood Products Advisory Committee.

European Health Forum 2003Reinhart Waneck1 Safety and Quality of Human Blood Products and Human Blood Derivatives in an Enlarged European Union The experience.

Faculty of Allied Medical Sciences Clinical Immunology & Serology Practice (MLIS 201)

BioLife Plasma Services Experience with HBV NAT Testing

Organ Donor Infectious Disease Testing Education UW Health OPO July 2009.

Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.

PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.

HCV Diagnosis. Features of Hepatitis C Virus Infection Incubation periodAverage 6-7 weeks Range 2-26 weeks Acute illness (jaundice)Mild (

IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.

21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-

RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.

Background Recruitment strategies for organ and tissue donors are different, and although some organ donors do eventually become tissue donors, organ donors.

Retrospective and Prospective U.S. Donor MRV Surveillance and Transmission Studies Michael Busch, MD, PhD Blood Systems Research Institute Dept of Laboratory.

Prevalence of Hepatitis B infection in married women of child bearing age in District Islamabad Dr. Najma Javeed Awan Senior Medical Officer Pakistan Medical.

KEY CONCEPT Some viral diseases can be prevented with vaccines.

Sensitivity of NAT blood screening assays in performance evaluation and proficiency programs Harry van Drimmelen, Nico Lelie, (VQC-Sanquin) and the principal.

1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.

SoGAT, Berne 2006BTS SRC Berne Ltd. Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd. Dr. Martin Stolz.

Module 1: The Journey of Blood: Donation to Distribution Transfusion Training Workshop KKM 2012.

Our tryst with Nucleic Acid Testing Dolly Daniel, Dept of Transfusion Medicine, CMC, Vellore.

Natural history of HBV infection (adapted from Torbenson Lancet 2003) Chronic infection Healthy carriage Recovery occult DNA Anti-HBe Anti-HBc Immune response.

NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.

Management of Donors and Units that Test HBV NAT Positive: Current Considerations July 21, 2005 BPAC Meeting Robin Biswas, M.D. FDA/CBER/OBRR/DETTD.

Serology - anti-HCV. anti-HIV, HBsAg NAT - HCV RNA - since 2000

A Universal Testing Programme for Blood Borne Viruses in an Urban Emergency Department – a call for widespread ED testing in Ireland S O’Connell 1, D Lillis.

Epidemiology of Transfusion Transmitted Disease Sharyn Orton, MT(ASCP)SBB, M.S.P.H, Ph.D. candidate Project Leader, Transmissible Diseases Department American.

February 24, 2016 | 1 Paul Strengers MD, FFPM Sanquin Blood Supply Amsterdam The Netherlands Risk assessment schemes: Impact of.

NAT as part of routine tests ? I disagree ! Dr Anjali Arun Mysore.

Evaluation of Hepatitis B surveillance system in Armenia, 2014 AUTHORS Karine Gevorgyan Lusine Paronyan Shushan Sargsyan Artavazd Vanyan NCDC, Armenia.

SoGAT May 2005 Are conversion factors to international units assay related? Marco Koppelman, Henk Reesink, Nico Lelie, Theo Cuypers.

Parallel and Overlapping Prevalence of Hepatitis B and C Viruses in Apparently Healthy Individuals in a Northern Nigerian Population Pennap, GRI and Chuga,

Relative Sensitivities of US Licensed NAT Assays for Detection of Viremia in Early HIV and HCV Infection MP Busch, SA Glynn, DJ Wright, D Hirschkorn, ME.

Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.

Donations After Reentry

Organ Donor Infectious Disease Testing Education

Implementing NAT& Universal Parasitic Screening for Blood Donors

R. Cavallo Clinical Microbiology and Infection

Italian EQA study for HCV RNA, HIV RNA and HBV DNA G. M. Bisso, K

NUCLEIC ACID AMPLIFICATION TESTING DETECTS HIV TRANSMISSION RISK IN SEROLOGICALLY- TESTED BLOOD DONOR UNITS. |Presented by Miss Shemau Muniru| Authors:

SoGAT meeting XXI May (2009), Brussels, Belgium

Assessment of risk factors for hepatocellular carcinoma in HIV care and treatment programs across 31 countries: a cross-sectional survey within IeDEA C.

ANALYTICAL CONTROL SYSTEM AS A MEASURE TO ENSURE INFECTIOUS SAFETY OF HUMAN PLASMA FOR FRACTIONATION A.L. Poptsov FSBI “ROSPLASMA” RMSPC of FMBA of RUSSIA.

Presentation transcript:

The effect of Nucleic acid testing (NAT) in the safety of blood transfusions F. Kourgia, M. Vini, E. Zervou Blood Centre of University Hospital of Ioannina, Ioannina, Greece

Around the world, more than 92 million blood donations are collected every year. From these, a single whole-blood donation can be transfused in up to three people, while blood-derived products from a single donation may be given to hundreds of patients. Laboratory screening of donated blood and blood products for infectious diseases is a key safety measure in protecting patients and preventing the spread of serious diseases.

In accordance with guidelines, the minimum requirements of blood testing include syphilis, HBV, HCV and HIV. In Greece HTLVI/II also is tested. The norm for viral testing has been serology, but increasingly NAT is been implemented where resources allow. NAT is a molecular technique used to detect a virus or a bacterium NAT improves the safety of transfusions because : -shortens the serological silent window period a time between when the donors have been infected and when they show up as positive by antibody or antigen tests and also -detects the cases of occult HBV (HbsAg -/anti-Hbc+)

HCV 4

HBV 5

HIV 6

Aim: To determine the NAT yield ( the infectious agent is not serologically detected but only by NAT) for HBV, HCV and HIV in the blood donations which conducted in the Blood Centre of University Hospital of Ioannina.

Methods: 2006-2014: 65.219 donations (62.460 for whole blood and 2.759 for platelets apheresis ) were tested For serological testing Abbott and Ortho assays were used. For individual (ID) NAT testing the Procleix Ultrio (Novartis) until the end of 2013 and after this time the Cobas AmpliPrep (Roche) were used.

Results: In this period: 1 case of HIV in the window period 17 cases of occult hepatitis B and 11 cases of possible occult hepatitis B (NAT initially reactive, anti-HBc positive but the repetition of NAT was negative, probably due to a low viral load) were identified.

Conclusion: The implementation of NAT detects infectious donations that could be missed by serological testing and so plays an important role in the safety of blood transfusions. In our center we found that the HBV NAT yield was 1/2.329 (1/3.836 clear occult HBV and 1/5.929 possible cases ) and the HIV NAT yield was 1/65.219 blood donations.

National data (SKAE) 2007-2013: ΝΑΤ yield in 3,240,394 blood donations Only NAT positive 8 HIV 1/405049 19 HCV 1/70547 436 HBV 1/7432

Thank you